Radiation Therapy
IMRT for Brain Cancer
"This trial is comparing a newer type of radiation therapy called intensity modulated radiation therapy (IMRT) to the standard whole brain radiation therapy for treating brain metastases. The study aims to see if IM
Monoclonal Antibodies
Trastuzumab Emtansine Safety for Cancer
This trial is for people who have been receiving treatment with either trastuzumab emtansine or a combination of it with other anti-cancer therapies, and who are still benefiting from the treatment. The purpose of the trial is to continue to monitor the safety of the treatment.
Monoclonal Antibodies
Pembrolizumab Combinations for Cancer
"This trial will test a drug called pembrolizumab in combination with other drugs in children with certain types of cancer. The study will have two parts: the first part will focus on safety and
Kinase Inhibitor
LOXO-435 for Bladder Cancer
This trial is testing LOXO-435, a new drug, to see if it can help treat advanced cancers with a specific genetic change. It aims to block a gene that helps cancer cells grow. The study will check the drug's safety and effectiveness in these patients. LOX may be a potential effective therapeutic target to treat colorectal cancer.
Popular Filters
Trials for Breast Cancer Patients
Selective Estrogen Receptor Downregulator (SERD)
Imlunestrant + Abemaciclib for Breast Cancer
This trial is testing a new drug called imlunestrant, alone and in combination with another drug, abemaciclib, for patients with advanced breast cancer that is ER+ and HER2-. Imlunestrant works by blocking estrogen receptors on cancer cells, while abemaciclib stops the cells from multiplying. The goal is to see if these treatments work better than standard hormone therapy.
CDK4/6 Inhibitor
Abemaciclib + Fulvestrant for Breast Cancer
This trial is testing a combination of two drugs, abemaciclib and fulvestrant, for treating a specific type of breast cancer that has not responded to previous treatments. Abemaciclib is taken orally and is approved for treating certain types of breast cancer. The goal is to see if this combination can help stop the cancer from growing. The study may last several years, depending on how well the treatment works for each patient.
Hormone Therapy
Vepdegestrant + Samuraciclib for Advanced Breast Cancer
This trial studies the safety & effects of vepdegestrant when given with other medicines for advanced metastatic breast cancer. Participants take vepdegestrant & samuraciclib pills daily & have visits every 4 weeks.
Trials for LABC Patients
Selective Estrogen Receptor Downregulator (SERD)
Imlunestrant + Abemaciclib for Breast Cancer
This trial is testing a new drug called imlunestrant, alone and in combination with another drug, abemaciclib, for patients with advanced breast cancer that is ER+ and HER2-. Imlunestrant works by blocking estrogen receptors on cancer cells, while abemaciclib stops the cells from multiplying. The goal is to see if these treatments work better than standard hormone therapy.
CDK4/6 Inhibitor
Abemaciclib + Fulvestrant for Breast Cancer
This trial is testing a combination of two drugs, abemaciclib and fulvestrant, for treating a specific type of breast cancer that has not responded to previous treatments. Abemaciclib is taken orally and is approved for treating certain types of breast cancer. The goal is to see if this combination can help stop the cancer from growing. The study may last several years, depending on how well the treatment works for each patient.
Hormone Therapy
Vepdegestrant + Samuraciclib for Advanced Breast Cancer
This trial studies the safety & effects of vepdegestrant when given with other medicines for advanced metastatic breast cancer. Participants take vepdegestrant & samuraciclib pills daily & have visits every 4 weeks.
Trials for Metastatic Patients
Selective Estrogen Receptor Downregulator (SERD)
Imlunestrant + Abemaciclib for Breast Cancer
This trial is testing a new drug called imlunestrant, alone and in combination with another drug, abemaciclib, for patients with advanced breast cancer that is ER+ and HER2-. Imlunestrant works by blocking estrogen receptors on cancer cells, while abemaciclib stops the cells from multiplying. The goal is to see if these treatments work better than standard hormone therapy.
Small Molecule Inhibitor
BI 1810631 for Advanced Cancer
This trial is testing a new medicine called BI 1810631, which is taken as tablets. It targets adults with advanced cancers that have specific genetic changes and have not responded to other treatments. The goal is to find a safe dose and see if it can help shrink tumors.
Chemotherapy
EMB-01 for Advanced Cancer
This trial is testing a new medicine called EMB-01 in patients with advanced cancers who have no other treatment options. EMB-01 aims to block two proteins that help cancer cells grow, making it harder for the cancer to survive.
PD-1 Inhibitor
Immunotherapy for Advanced Cancer
This trial is testing a new immunotherapy in adults with advanced cancer. The goal is to see if it helps the immune system fight cancer, and if it's well-tolerated. Participants will be in the study for varying lengths of time, depending on how well they respond to treatment and if they experience any side effects.
Trials for ER Positive Patients
Selective Estrogen Receptor Downregulator (SERD)
Imlunestrant + Abemaciclib for Breast Cancer
This trial is testing a new drug called imlunestrant, alone and in combination with another drug, abemaciclib, for patients with advanced breast cancer that is ER+ and HER2-. Imlunestrant works by blocking estrogen receptors on cancer cells, while abemaciclib stops the cells from multiplying. The goal is to see if these treatments work better than standard hormone therapy.
Simvastatin + Anti-HER2 Therapy for Breast Cancer
This trial tests if adding simvastatin, a cholesterol-lowering drug, to the current treatment can help patients with advanced breast cancer that has spread and is not responding to usual treatments. The goal is to see if this combination can make the cancer treatment work better. Simvastatin, originally used to lower cholesterol, has been studied since the 1990s for its potential anticancer effects, including in breast cancer.
Trials for PR Positive Patients
Simvastatin + Anti-HER2 Therapy for Breast Cancer
This trial tests if adding simvastatin, a cholesterol-lowering drug, to the current treatment can help patients with advanced breast cancer that has spread and is not responding to usual treatments. The goal is to see if this combination can make the cancer treatment work better. Simvastatin, originally used to lower cholesterol, has been studied since the 1990s for its potential anticancer effects, including in breast cancer.
Poly (ADP-ribose) polymerase (PARP) inhibitor
Veliparib + Carboplatin for Breast Cancer
This trial is testing the combination of veliparib and carboplatin to treat patients with HER2-negative breast cancer that has spread. Veliparib may help carboplatin kill more cancer
Phase 3 Trials
Selective Estrogen Receptor Downregulator (SERD)
Imlunestrant + Abemaciclib for Breast Cancer
This trial is testing a new drug called imlunestrant, alone and in combination with another drug, abemaciclib, for patients with advanced breast cancer that is ER+ and HER2-. Imlunestrant works by blocking estrogen receptors on cancer cells, while abemaciclib stops the cells from multiplying. The goal is to see if these treatments work better than standard hormone therapy.
Monoclonal Antibodies
LY3537982 + Immunotherapy/Chemotherapy for Non-Small Cell Lung Cancer
This trial is testing a new drug, LY3537982, combined with standard treatments for patients with advanced lung cancer that have a specific genetic mutation. The goal is to see if this combination works better than the usual treatments alone.
CDK4/6 Inhibitor
Abemaciclib + Fulvestrant for Breast Cancer
This trial is testing a combination of two drugs, abemaciclib and fulvestrant, for treating a specific type of breast cancer that has not responded to previous treatments. Abemaciclib is taken orally and is approved for treating certain types of breast cancer. The goal is to see if this combination can help stop the cancer from growing. The study may last several years, depending on how well the treatment works for each patient.
Monoclonal Antibodies
Atezolizumab + Standard Therapy for HER2-Positive Breast Cancer
This trial is studying how well paclitaxel, trastuzumab, and pertuzumab with or without atezolizumab works in treating patients with breast cancer that has spread to other parts of the body (metastatic).
Trials With No Placebo
Selective Estrogen Receptor Downregulator (SERD)
Imlunestrant + Abemaciclib for Breast Cancer
This trial is testing a new drug called imlunestrant, alone and in combination with another drug, abemaciclib, for patients with advanced breast cancer that is ER+ and HER2-. Imlunestrant works by blocking estrogen receptors on cancer cells, while abemaciclib stops the cells from multiplying. The goal is to see if these treatments work better than standard hormone therapy.
Small Molecule Inhibitor
BI 1810631 for Advanced Cancer
This trial is testing a new medicine called BI 1810631, which is taken as tablets. It targets adults with advanced cancers that have specific genetic changes and have not responded to other treatments. The goal is to find a safe dose and see if it can help shrink tumors.
Behavioural Intervention
Communication Intervention for Dementia
This trial is testing whether or not the Jumpstart intervention can improve patient-centered outcomes for those with chronic illness. The study will specifically look at Alzheimer's disease and related dementias, but will also include other common chronic illnesses. The trial will assess the efficacy of the intervention by measuring quality of care, intensity of care outcomes, and patient- and family-reported outcomes. There will also be a mixed-methods evaluation of the implementation of the intervention to explore barriers and facilitators to future implementation and dissemination.
Chemotherapy
EMB-01 for Advanced Cancer
This trial is testing a new medicine called EMB-01 in patients with advanced cancers who have no other treatment options. EMB-01 aims to block two proteins that help cancer cells grow, making it harder for the cancer to survive.
PD-1 Inhibitor
Immunotherapy for Advanced Cancer
This trial is testing a new immunotherapy in adults with advanced cancer. The goal is to see if it helps the immune system fight cancer, and if it's well-tolerated. Participants will be in the study for varying lengths of time, depending on how well they respond to treatment and if they experience any side effects.
View More Related Trials
Frequently Asked Questions
Introduction to metastatic breast cancer
What are the top hospitals conducting metastatic breast cancer research?
When it comes to cutting-edge clinical trials for metastatic breast cancer, several renowned hospitals across the United States are leading the charge. In Saint Louis, Washington University School of Medicine is at the forefront with nine ongoing trials focused specifically on this aggressive form of breast cancer. Since recording their first trial in 2008, they have conducted a total of 15 studies dedicated to metastatic breast cancer. Meanwhile, Memorial Sloan Kettering Cancer Center in New york has been tackling this challenging condition since 2003, currently running eight active trials and having completed an impressive 64 past trials.
In Boston's medical landscape, two prominent institutions are also making significant contributions. Dana Farber Cancer Institute boasts seven ongoing clinical trials for metastatic breast cancer and a commendable track record of conducting 26 previous studies since initiating their first trial in 2007. Another institution within the city - Dana-Farber Cancer Institute - shares a similar name but maintains its own distinct accomplishments. With seven active trials and a history encompassing 34 past investigations dating back to their pioneering study in1999.
Massachusetts General Hospital joins these esteemed hospitals with six current clinical tests focusing on metastatic breast cancer while having accomplished thirty-six prior successful research initiatives from as early as back in yearsof2003. These remarkable efforts by top institutions emphasize the urgency placed upon understanding and treating metastatic breast cancer—a condition where the disease spreads beyond the initial site to other parts of the body—proving that through relentless commitment to research and innovation we come ever closer towards finding effective treatments or potentially even cures for this devastating illness that affects so many lives worldwide
Which are the best cities for metastatic breast cancer clinical trials?
When it comes to metastatic breast cancer clinical trials, several cities stand out as leaders in research and development. New york City has 35 active trials focusing on promising treatments like Abemaciclib, Sacituzumab Govitecan-hziy, and Giredestrant. Boston also stands strong with 34 ongoing studies exploring innovative approaches such as Abemaciclib, PF-07265807, and ABT-888. Honolulu shines in the field with 32 active trials investigating therapies like Palbociclib and Serum Tumor Marker directed disease monitoring. Houston follows closely behind with 29 trials studying Simvastatin 80mg, Giredestrant, nab-sirolimus, among others. Finally, Nashville dedicates its efforts to advancing care through 24 active trials centered around treatments like Abemaciclib, 9-ING-41,and ARV-471. These cities offer individuals battling metastatic breast cancer access to cutting-edge clinical trials that hold promise for improved outcomes and better quality of life.
Which are the top treatments for metastatic breast cancer being explored in clinical trials?
Exciting advancements are being made in the field of metastatic breast cancer research, with several top treatments showing promise in clinical trials. Leading the pack is abemaciclib, currently undergoing exploration in five active trials for metastatic breast cancer. With its first listing dating back to 2014, it has garnered a respectable tally of 12 all-time trials dedicated to addressing this challenging disease. Trastuzumab follows closely behind, participating in three ongoing trials and boasting an impressive record of 19 all-time clinical studies since its introduction in 2006. Also making waves are talazoparib and trastuzumab deruxtecan—relatively newer additions that show great potential with three active trials each. These groundbreaking treatments offer hope for improved outcomes for individuals battling metastatic breast cancer.
What are the most recent clinical trials for metastatic breast cancer?
Exciting advancements in clinical trials for metastatic breast cancer offer hope and potential progress in the treatment of this challenging disease. One such trial focuses on elacestrant, a Phase 2 study that aims to evaluate its efficacy specifically for metastatic breast cancer patients. Additionally, a Phase 3 trial explores the combination of Inavolisib and Fulvestrant as a potential treatment option. Another promising approach involves combining ARV-471 with Abemaciclib, with both Phase 1 and Phase 2 trials investigating its effectiveness against metastatic breast cancer. Furthermore, ongoing research includes a Phase 1b cohort examining LOXO-435 monotherapy dose expansion and evaluating the impact of injections at varying doses. With these recent clinical trials paving the way forward, there is renewed optimism for improved outcomes in individuals facing metastatic breast cancer.
What metastatic breast cancer clinical trials were recently completed?
In recent years, several clinical trials have contributed to the advancement of treatments for metastatic breast cancer. Mirati Therapeutics Inc.'s MRTX849 trial concluded in August 2021, while I-Mab Biopharma Co. Ltd.'s TJ210001 trial ended in December 2020. In October and August of that same year, Merck Sharp & Dohme Corp. and Blue Earth Diagnostics completed their respective trials involving Pembrolizumab and 18F fluciclovine. These studies highlight ongoing efforts to find effective therapeutic options for patients facing this challenging condition, encouraging greater hope within the medical community and among those affected by metastatic breast cancer.